Thinly traded nano cap EyeGate Pharmaceuticals (EYEG +22.4%) is up on almost a 4x surge in volume, albeit on turnover of only 82K shares, on no particular news.
A key looming event is the release of data from a pivotal study evaluating its Ocular Bandage Gel eye drop in patients undergoing photorefractive keratectomy (laser surgery on the eye for vision correction). Randomization was completed a month ago with topline results expected by year-end. If all goes well, it expects to file a U.S. marketing application in H1 2020.
On the working capital front, at the end of June, it had $4.7M in cash and equivalents while operations consumed $3.6M in H1.
On October 18, it filed an S-3 for the resale of 1.2M common shares from current stockholders.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.